(493f) Rapid, High Throughput mRNA Purification.

FDA Emergency Use Authorization of mRNA-based COVID-19 vaccines is a critical milestone in mRNA medicines and foreshadow the high growth potential of mRNA drugs. However, CEO of a leading pharmaceutical mRNA company suggested the quantity and quality, i.e. consistent purity, of mRNA remain as bottlenecks for their production. Particularly, the lack of high-throughput downstream purification processes is a major challenge in the upscaling of industrial mRNA production. There are few commercially available mRNA affinity purification tools, especially for process scale operations. Purilogics is presenting a novel mRNA affinity membrane designed for rapid purifications. In this presentation, we will compare the effect of flowrate and mRNA size on the binding capacity and recovery of our membrane product against the current gold standard commercial mRNA affinity resin product. Additionally, purifications assessing purity and yield from industrially relevant in vitro transcription reactions will be demonstrated.